BАYER BEGINS INTERNATIONAL CLINICAL TRIALS IN KAZAKHSTAN

At the site of the III International Pharmaceutical Forum "Global Pharm", the Ministry of Health of the Republic of Kazakhstan and Bayer KAZ LLP entered into a Memorandum of Cooperation and Mutual Understanding. The joint strategic partnership is aimed at developing the clinical research market and transferring advanced technologies.

Bayer is one of the world's leaders in developing and marketing innovative medicines that benefit patients in therapeutic areas such as cardiology, oncology, women's health, diabetes and ophthalmology.

In therapeutic radiology, Bayer is focused on developing IT applications, infusion systems and contrast agents for low-dose computed tomography (CT) and high-field magnetic resonance imaging (MRI), which enable physicians to make more accurate diagnoses and thereby reduce direct healthcare costs. , obtaining quality data.

The parties reached an agreement to attract international randomized clinical trials of unique innovative drugs to Kazakhstan that change the paradigm of disease treatment. Also, joint work is envisaged on market access for innovative products for the treatment of prostate cancer to provide patients with innovative methods of therapy and improve the competencies of healthcare professionals in Kazakhstan through the implementation of scientific and educational programs.

The international pharmaceutical forum “Global Pharm” rightfully retains its status as the most effective dialogue platform for identifying new development opportunities and searching for reliable business partnerships. During the forum, Kazakhstan signed five Memorandums of Cooperation with domestic and foreign companies, including from BigPharma.

The head of state has repeatedly noted the importance of cooperation with global players and technology transfer, instructing to increase the share of domestic medicines to 50%.

The Kazakh side, for its part, expressed gratitude and readiness to cooperate for the promotion and development of the domestic pharmaceutical sector. Joint interaction will give a new impetus to the development of the Kazakh pharmaceutical market through the introduction of global practices from BigPharma companies.